Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs

This publication has 55 references indexed in Scilit:

• The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients
  Cancer Research, 2005
• Investigation of Efflux Transport of Dehydroepiandrosterone Sulfate and Mitoxantrone at the Mouse Blood-Brain Barrier: A Minor Role of Breast Cancer Resistance Protein
  The Journal of Pharmacology and Experimental Therapeutics, 2005
• Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice
  Cancer Research, 2004
• Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein
  European Journal Of Cancer, 2004
• Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• Phase II and Pharmacologic Study of Weekly Oral Paclitaxel Plus Cyclosporine in Patients With Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2002
• Transport of 7-Ethyl-10-hydroxycamptothecin (SN-38) by Breast Cancer Resistance Protein ABCG2 in Human Lung Cancer Cells
  Biochemical and Biophysical Research Communications, 2001
• Functional Characterization of the Human Multidrug Transporter, ABCG2, Expressed in Insect Cells
  Biochemical and Biophysical Research Communications, 2001
• Genetic dissection of the function of mammalian P-glycoproteins
  Trends in Genetics, 1997
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
  Journal of Clinical Investigation, 1995